EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination

Muge Didem Orhan, Lalehan Oktay, Ayşe Irem Cınar, Aybek Kagan Yesil, Huseyin Tunc iD, Fatih Eren, Serdar Durdagi, Timucin Avsar iD

ACS Chemical Neuroscience · 2025

DOI: 10.1021/acschemneuro.5c00519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Muge Didem Orhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience, Graduate School of Education, Bahçeşehir University, Istanbul 34353, Turkey. Hauptthemen laut MEDLINE: Piperidines, Interleukin-17, Indazoles, Remyelination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Arastirma Kurumu, Bahçesehir Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IL-17A is a pro-inflammatory cytokine that significantly contributes to the pathogenesis of autoimmune diseases, including multiple sclerosis (MS). Previous studies have suggested that PARP-1 inhibitors can modulate IL-17A-mediated inflammation, prompting the investigation of Niraparib, an FDA-approved PARP-1 inhibitor, as a potential therapeutic agent for MS. In this study, we hypothesized that Niraparib could disrupt the interaction between IL-17A and its receptor, IL-17RA. To evaluate this, we employed a binary quantitative structure-activity relationship (QSAR) model against anti-inflammatory diseases, which indicated Niraparib's potential efficacy against MS. In silico analyses were conducted to identify key interaction sites and critical amino acid residues involved in the IL-17A/IL-17RA binding. Molecular docking simulations demonstrated Niraparib's capability to interfere with these interactions. It has demonstrated significant efficacy in inhibiting the interaction between the IL-17A ligand and its receptor via reporter assay. In vivo assessments were performed using a cuprizone-induced demyelination model. Immune profiling revealed modulation of various T cell subsets and B cells, while cytokine analysis indicated a shift in inflammatory responses. Histological evaluations confirmed reduced demyelination and enhanced remyelination in affected brain regions. These findings support Niraparib's potential as a therapeutic option for MS, warranting further exploration of its mechanisms and clinical relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesInterleukin-17IndazolesRemyelinationReceptors, Interleukin-17Multiple SclerosisPoly(ADP-ribose) Polymerase InhibitorsAnimalsMolecular Docking SimulationMiceHumansEncephalomyelitis, Autoimmune, ExperimentalMice, Inbred C57BLFemale

Stichwörter der Autor:innen

IL-17APARP-1 inhibitorcuprizone mouse modeldemyelinationmultiple sclerosisniraparib

Substanzen

PiperidinesInterleukin-17niraparibIndazolesReceptors, Interleukin-17Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Neuroscience, Graduate School of Education, Bahçeşehir University, Istanbul 34353, Turkey.
  • Department of Medical Biology, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
  • Neurooncology Laboratory, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
  • Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
  • Lab for Innovative Drugs (Lab4IND), Computational Drug Design Center (HITMER), Bahçeşehir University, Istanbul 34353, Turkey.
  • Neuroscience Program, University of Bonn, Bonn 53113, Germany.

ORCID-Profile: Huseyin Tunc, Timucin Avsar

Förderung

  • Türkiye Bilimsel ve Teknolojik Arastirma Kurumu
  • Bahçesehir Üniversitesi

Zitieren

APA

Orhan, M. D., Oktay, L., Cınar, A. I., Yesil, A. K., Tunc, H., Eren, F., Durdagi, S., & Avsar, T. (2025). Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00519

Vancouver

Orhan MD, Oktay L, Cınar AI, Yesil AK, Tunc H, Eren F, et al. Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00519

BibTeX
@article{Orhan2025,
  author = {Orhan, Muge Didem and Oktay, Lalehan and Cınar, Ayşe Irem and Yesil, Aybek Kagan and Tunc, Huseyin and Eren, Fatih and Durdagi, Serdar and Avsar, Timucin},
  title = {Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination},
  journal = {ACS Chemical Neuroscience},
  year = {2025},
  doi = {10.1021/acschemneuro.5c00519}
}
Kostenlos starten →